s. pneumonia

Garenoxacin (BMS284756) is a novel oral des-fluoro(6) quinolone for the treatment of Gram-positive and Gram-negative bacterial infections.

Garenoxacin mesylate hydrate (Garenoxacin mesylate [USAN]) with potent antimicrobial activity, against common respiratory pathogens, including resistant strains.

NSC 55655 (5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione) possesses antimicrobial and antioxidant activities and inhibits the proliferation of B. subtilis, S. aureus, K. pneumonia, E. coli, S. typhi , A. niger and C. albicans. A. niger and C. albicans, and can be used in diabetes mellitus.

Clinafloxacin (CI-960)(PD-127391) is a fluoroquinolone antibiotic.

Lysionotin (Nevadensin) has expectorant, eliminating phlegm, softening effects.

Hirsutide is a cyclotetrapeptide fungal metabolite produced by the entomopathogenic fungus Hirsutella. It has antibacterial activity against C. pyogenes, S. aureus, P. aeruginosa, and K. pneumonia (MICs = 25, 13, 6, and 21 μg/cm3, respectively). Hirsutide also has antifungal activity against C. albicans, M. audouinii, A. niger, and Ganoderma (MICs = 13, 6, 25, and 6 μg/cm3, respectively).

Lanopepden, also known as GSK-1322322 or GSK-322, is a potent and selective peptide deformylase inhibitor with good in vitro activity against bacteria associated with community-acquired pneumonia and skin infections. GSK1322322 had bactericidal activity against S. pneumoniae, H. influenzae, S. pyogenes, and S. aureus, demonstrating a ≥ 3-log(10) decrease in the number of CFU ml at 4× MIC within 24 h in 29 of the 33 strains tested. GSK1322322 represents a valuable alternative therapy for the treatment of infectious diseases caused by drug-resistant pathogens.

Poly(I:C):Kanamycin (1:1) sodium is a complex.Poly(I:C) is a synthetic double-stranded RNA analogue and a TLR3 and RIG-I MDA5 agonist that enhances immunity and promotes apoptosis in cancer cells.Kanamycin is an antimicrobial agent that is effective against both Gram-negative and positive bacteria which is able to bind the 70S ribosomal subunit.

Tosatoxumab (AR-301; KBSA301), a human immunoglobulin G1 monoclonal antibody, specifically targets and neutralizes S. aureus alpha-toxin (alpha-hemolysin; Hla) by binding to its N-terminal epitope. This interaction blocks the toxin's ability to form functional pore oligomers, crucial for its pathogenic activity. As a result, Tosatoxumab offers promising potential as an adjunctive passive immunotherapy alongside conventional antibiotics for S. aureus pneumonia [1] [2].

Suvratoxumab (MEDI4893) is a high-affinity, long-acting humanized IgG1κ anti-α-toxin monoclonal antibody. It effectively neutralizes α-toxin, a principal virulence factor of S. aureus, enhancing survival and diminishing lung injury in an immunocompromised mouse model of pneumonia. Additionally, Suvratoxumab augments the antibacterial efficacy of Vancomycin and Linezolid [1] [2] [3].

COX-1 2-IN-9 (Compound 3n) serves as a selective and potent inhibitor of both COX-1 and COX-2, demonstrating IC 50 values of 0.031 µM for COX-1 and 0.01 µM for COX-2. This compound exhibits antibacterial and anti-inflammatory properties, effectively targeting MRSA 1478 (MIC=50 μg mL) and multidrug-resistant S. lentus (MIC=50 μg mL). Furthermore, COX-1 2-IN-9 shows promise in relieving MRSA-induced pneumonia in conditions of compromised immunity.